Lataa...
MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
BACKGROUND: MEK and BRAF inhibitors are increasingly common treatments for pediatric nervous system tumors. While effective in blocking Ras/Raf/MEK/ERK pathway activation driving tumor progression, the side effect profile differs from traditional cytotoxic chemotherapies. Little data exists on overl...
Tallennettuna:
| Julkaisussa: | Neuro Oncol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7715474/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.578 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|